Search

Your search keyword '"Feliciani C"' showing total 559 results
Start Over Author "Feliciani C"
559 results on '"Feliciani C"'

3. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis

Author

Stingeni, L., Bianchi, L., Antonelli, E., Caroppo, E. S., Ferrucci, S. M., Gurioli, C., Ortoncelli, M., Fabbrocini, G., Nettis, E., Schena, D., Napolitano, M., Gola, M., Bonzano, L., Rossi, M., Belloni Fortina, A., Balato, A., Peris, Ketty, Foti, C., Guarneri, F., Romanelli, M., Patruno, C., Savoia, P., Esposito, M., Russo, F., Errichetti, E., Bianchelli, T., Pellacani, G., Feliciani, C., Offidani, A., Corazza, M., Micali, G., Milanesi, N., Malara, G., Chiricozzi, Andrea, Tramontana, M., Hansel, K., Buligan, C., Caroppo, F., Bello, G. D., Dastoli, S., Di Brizzi, E. V., Del Giudice, M. B. D. F., Diluvio, L., Fargnoli, Maria Concetta, Gelmetti, A., Giacchetti, A., Grieco, T., Iannone, M., Macchia, L., Marietti, R., Musumeci, M. L., Motolese, A., Neri, I., Radi, G., Ribero, S., Romita, P., Tavecchio, S., Tronconi, G., Veronese, F., Stingeni, Luca, Bianchi, Leonardo, Antonelli, Elettra, Caroppo, Elena Sofia, Ferrucci, Silvia Mariel, Gurioli, Carlotta, Ortoncelli, Michela, Fabbrocini, Gabriella, Nettis, Eustachio, Schena, Donatella, Napolitano, Maddalena, Gola, Massimo, Bonzano, Laura, Rossi, Mariateresa, Belloni Fortina, Anna, Balato, Anna, Peris, Ketty, Foti, Caterina, Guarneri, Fabrizio, Romanelli, Marco, Patruno, Cataldo, Savoia, Paola, Esposito, Maria, Russo, Filomena, Errichetti, Enzo, Bianchelli, Tommaso, Bianchi, Luca, Pellacani, Giovanni, Feliciani, Claudio, Offidani, Annamaria, Corazza, Monica, Micali, Giuseppe, Milanesi, Nicola, Malara, Giovanna, Chiricozzi, Andrea, Tramontana, Marta, and Hansel, Katharina

Subjects
Infectious Diseases, atopic dermatitis, dupilumab, Dermatology, Settore MED/35 - MALATTIE CUTANEE E VENEREE
Published
2023

4. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience

Author

Stingeni, L., Bianchi, L., Antonelli, E., Caroppo, E. S., Ferrucci, S. M., Ortoncelli, M., Fabbrocini, G., Nettis, E., Schena, D., Napolitano, M., Gola, M., Bonzano, L., Rossi, M., Belloni Fortina, A., Balato, A., Peris, K., Foti, C., Guarneri, F., Romanelli, M., Patruno, C., Savoia, P., Fargnoli, M. C., Russo, F., Errichetti, E., Bianchelli, T., Pellacani, G., Feliciani, C., Offidani, A., Corazza, M., Micali, G., Milanesi, N., Malara, G., Chiricozzi, A., Tramontana, M., Hansel, K., Bini, V., Buligan, C., Caroppo, F., Dal Bello, G., Dastoli, S., Di Brizzi, E. V., De Felici Del Giudice, M. B., Diluvio, L., Esposito, M., Gelmetti, A., Giacchetti, A., Grieco, T., Iannone, M., Macchia, L., Marietti, R., Musumeci, M. L., Peccerillo, F., Pluchino, F., Radi, G., Ribero, S., Romita, P., Tavecchio, S., Tronconi, G., Veronese, F., Stingeni, L, Bianchi, L, Antonelli, E, Caroppo, E S, Ferrucci, S M, Ortoncelli, M, Fabbrocini, G, Nettis, E, Schena, D, Napolitano, M, Gola, M, Bonzano, L, Rossi, M, Belloni Fortina, A, Balato, A, Peris, K, Foti, C, Guarneri, F, Romanelli, M, Patruno, C, Savoia, P, Fargnoli, M C, Russo, F, Errichetti, E, Bianchelli, T, Pellacani, G, Feliciani, C, Offidani, A, Corazza, M, Micali, G, Milanesi, N, Malara, G, Chiricozzi, A, Tramontana, M, and Hansel, K

Subjects
SARS-CoV-2, Pruritus, Eczema, COVID-19, Dermatitis, Dermatology, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Atopic, Antibodies, COVID-19 Drug Treatment, Dermatitis, Atopic, Treatment Outcome, Settore MED/35, Infectious Diseases, Double-Blind Method, Monoclonal, Humans, Prospective Studies, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Pandemics, Humanized
Abstract

Background Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. Objectives A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from >= 12 to

Published
2022

5. Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study

Author

Bardazzi, F., primary, Filippi, F., additional, Chessa, M.A., additional, Iommi, M., additional, Loi, C., additional, Campanati, A., additional, Rizzetto, G., additional, Tagliati, C., additional, Atzori, L., additional, Muratori, S., additional, Genovese, G., additional, Gisondi, P., additional, Schena, D., additional, Balestri, R., additional, Rech, G., additional, Feliciani, C., additional, Lasagni, C., additional, Bigi, L., additional, De Simone, C., additional, Di Zenzo, G., additional, Moro, F., additional, Borghi, A., additional, Di Lernia, V., additional, D'Arrigo, G., additional, Tripepi, G., additional, Gori, M., additional, and Pitino, A., additional

Published
2022
Full Text
View/download PDF

7. Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt)

Author

Papini, M., Russo, A., Simonetti, O., Borghi, A., Corazza, M., Piaserico, S., Feliciani, C., Calzavara-Pinton, P., Amendolagine, G., Arisi, M., Babino, G., Bardazzi, F., Belloni Fortina, A., Cac-Cavale, S., Campanati, A., Campione, E., Caposiena, C. D., Carugno, A., Coati, I., Cinotti, E., D'Antuono, A., Dattola, A., Dika, E., Fai, D., Fusano, M., Galluzzo, M., Ganzetti, G., Gisondi, P., Hansel, K., Lora, V., Maione, V., Mandel, V. D., Menni, S., Negosanti, M., Neri, I., Offidani, A., Parodi, A., Patrizi, A., Peserico, A., Rossi, M., Rivetti, N., Saccani, E., Stan, T. R., Stingeni, L., Talamonti, M., Vascellaro, A., Vezzoli, P., Virgili, A., Zanca, A., Papini, M., Russo, A., Simonetti, O., Borghi, A., Corazza, M., Piaserico, S., Feliciani, C., Calzavara-Pinton, P., Amendolagine, G., Arisi, M., Babino, G., Bardazzi, F., Belloni Fortina, A., Caccavale, S., Campanati, A., Campione, E., Caposiena, C. D., Carugno, A., Coati, I., Cinotti, E., D'Antuono, A., Dattola, A., Dika, E., Fai, D., Fusano, M., Galluzzo, M., Ganzetti, G., Gisondi, P., Hansel, K., Lora, V., Maione, V., Mandel, V. D., Menni, S., Negosanti, M., Neri, I., Offidani, A., Parodi, A., Patrizi, A., Peserico, A., Rossi, M., Rivetti, N., Saccani, E., Stan, T. R., Stingeni, L., Talamonti, M., Vascellaro, A., Vezzoli, P., Virgili, A., Zanca, A., Papini, M, Russo, A, Simonetti, O, Borghi, A, Corazza, M, Piaserico, S, Feliciani, C, Calzavara-Pinton, P, Amendolagine, G, Arisi, M, Babino, G, Bardazzi, F, Belloni Fortina, A, Cac-Cavale, S, Campanati, A, Campione, E, Caposiena, C, Carugno, A, Coati, I, Cinotti, E, D'Antuono, A, Dattola, A, Dika, E, Fai, D, Fusano, M, Galluzzo, M, Ganzetti, G, Gisondi, P, Hansel, K, Lora, V, Maione, V, Mandel, V, Menni, S, Negosanti, M, Neri, I, Offidani, A, Parodi, A, Patrizi, A, Peserico, A, Rossi, M, Rivetti, N, Saccani, E, Stan, T, Stingeni, L, Talamonti, M, Vascellaro, A, Vezzoli, P, Virgili, A, Zanca, A, Papini M., Russo A., Simonetti O., Borghi A., Corazza M., Piaserico S., Feliciani C., Calzavara-Pinton P., Amendolagine G., Arisi M., Babino G., Bardazzi F., Belloni Fortina A., Cac-Cavale S., Campanati A., Campione E., Caposiena C.D., Carugno A., Coati I., Cinotti E., D'Antuono A., Dattola A., Dika E., Fai D., Fusano M., Galluzzo M., Ganzetti G., Gisondi P., Hansel K., Lora V., Maione V., Mandel V.D., Menni S., Negosanti M., Neri I., Offidani A., Parodi A., Patrizi A., Peserico A., Rossi M., Rivetti N., Saccani E., Stan T.R., Stingeni L., Talamonti M., Vascellaro A., Vezzoli P., Virgili A., and Zanca A.

Subjects
Male, medicine.medical_specialty, Calcineurin Inhibitors, Socio-culturale, Disease, Dermatology, Lichen sclerosus, Guideline, Settore MED/35, Lichen sclerosus et atrophicu, medicine, Dysuria, Humans, Sex organ, Drug therapy, Lichen sclerosus et atrophicus, Operative surgical procedures, Rare diseases, Vulvar lichen sclerosus, Female, Italy, Mometasone Furoate, Lichen Sclerosus et Atrophicus, Calcineurin Inhibitor, business.industry, Mucous membrane, Evidence-based medicine, medicine.disease, Infectious Diseases, medicine.anatomical_structure, Sexual dysfunction, Operative surgical procedure, Vulvar lichen sclerosu, medicine.symptom, business, Rare disease, Human
Abstract

Lichen sclerosus (LS) is a disabling chronic inflammatory disease of skin and genital mucous membrane causing itch, pain, dysuria and restriction of micturition, and significant sexual dysfunction and dyspareunia both in women and men. If left untreated, LS is associated with a high degree of sclerosis and scarring, as well as with an elevated risk of cancer in the genital area. Although a central role of autoimmunity is suggested, the pathogenesis of LS is still not clearly understood and the disease remains difficult to treat. The goals of treatment of LS are to alleviate symptoms and discomfort, prevent anatomical changes and prevent malignant transformation. This guideline has been developed by an Italian group of experts. It summarizes evidence-based and expert- based recommendations. The highest level of evidence favors the use of topical high potency corticosteroids; second- and third-line treatments include topical calcineurin inhibitors and topical retinoids, respectively. Surgical treatment has become the treatment of choice in male genital LS with persistent phimosis not responsive to medical treatment. The aim of this paper is to offer evidence-based and easily applicable recommendations for the management of LS.

Published
2021

9. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

Author

Borradori, L., primary, Van Beek, N., additional, Feliciani, C., additional, Tedbirt, B., additional, Antiga, E., additional, Bergman, R., additional, Böckle, B. C., additional, Caproni, M., additional, Caux, F., additional, Chandran, N.S., additional, Cianchini, G., additional, Daneshpazhooh, M., additional, De, D., additional, Didona, D., additional, Di Zenzo, G. M., additional, Dmochowski, M., additional, Drenovska, K., additional, Ehrchen, J., additional, Goebeler, M., additional, Groves, R., additional, Günther, C., additional, Horvath, B., additional, Hertl, M., additional, Hofmann, S., additional, Ioannides, D., additional, Itzlinger‐Monshi, B., additional, Jedličková, J., additional, Kowalewski, C., additional, Kridin, K., additional, Lim, Y. L., additional, Marinovic, B., additional, Marzano, A. V., additional, Mascaro, J.‐M., additional, Meijer, J.M., additional, Murrell, D., additional, Patsatsi, K., additional, Pincelli, C., additional, Prost, C., additional, Rappersberger, K., additional, Sárdy, M., additional, Setterfield, J., additional, Shahid, M., additional, Sprecher, E., additional, Tasanen, K., additional, Uzun, S., additional, Vassileva, S., additional, Vestergaard, K., additional, Vorobyev, A., additional, Vujic, I., additional, Wang, G., additional, Wozniak, K., additional, Yayli, S., additional, Zambruno, G., additional, Zillikens, D., additional, Schmidt, E., additional, and Joly, P., additional

Published
2022
Full Text
View/download PDF

11. Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis. The LION real-life multicenter prospective observational cohort study

Author

Campanati, A., Atzori, L., Potenza, C., Damiani, G., Bianchi, L., Corazza, M., Tiberio, R., Prignano, F., Argenziano, G., Fargnoli, M. C., Stingeni, L., Mazzotta, A., De Pita, O., Mazzatenta, C., Feliciani, C., Donini, M., Offidani, A., Peris, K., Rongioletti, F., Pigatto, P., Cruciani, G., De Simone, C., Caldarola, G., Grimaldi, M., Anedda, J., Bernardini, N., Marchesiello, A., Franchi, C., Dattola, A., Botti, E., Zedde, P., Cammarata, E., Radi, G., Rosi, E., De Rosa, A., Esposito, M., Marietti, R., Lupi, F., Grazzini, M., Domenico, D. M., Brusasco, M., Gai, F., Campanati, A., Atzori, L., Potenza, C., Damiani, G., Bianchi, L., Corazza, M., Tiberio, R., Prignano, F., Argenziano, G., Fargnoli, M. C., Stingeni, L., Mazzotta, A., De Pita, O., Mazzatenta, C., Feliciani, C., Donini, M., Offidani, A., Peris, K., Rongioletti, F., and on behalf of the LION study group—Italian Participating, Centers

Subjects
Adult, Male, medicine.medical_specialty, Dermatologic Agent, psoriasis, therapy-topical, Betamethasone dipropionate, Dermatology, Betamethasone, NO, chemistry.chemical_compound, Patient satisfaction, Calcitriol, Psoriasis, Internal medicine, Drug Combination, medicine, Humans, Prospective Studies, Prospective cohort study, Calcipotriol, psoriasi, therapy-topical, business.industry, psoriasis, General Medicine, Middle Aged, medicine.disease, Prospective Studie, Drug Combinations, Treatment Outcome, chemistry, Patient Satisfaction, Cohort, Observational study, Dermatologic Agents, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business, Cohort study, medicine.drug, Human
Abstract

Topical treatment is the mainstay for mild or moderate psoriasis, but patients are generally little satisfied. Calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam has shown to improve signs and symptoms in plaque psoriasis patients. This study assessed patient's satisfaction with Cal/BD foam in a real-life Italian dermatological clinical practice. A multicenter, 4-week observational prospective cohort study enrolled, in 17 Italian dermatology clinics, adult patients with plaque psoriasis on the body and/or scalp. Treatment satisfaction was assessed by 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), preference over previous treatments by Patient Preference Questionnaire (PPQ), and change in disease state by Psoriasis Area Severity Index (PASI). Overall 256 patients were eligible, with a mean (SD) age of 55.6 (15.4) years, 59.4% were males. Psoriasis severity was mild in 52.0% of patients, moderate in 43.3%, and severe in 4.7%. Scalp involvement was present in 36.7% of patients. Previous antipsoriatic treatments had been received by 80.5% of patients. TSQM-9 median (25th-75th percentile) scores were 83.3 (66.7-88.9) for effectiveness, 77.8 (66.7-88.9) for convenience, and 78.6 (64.3-92.9) for global satisfaction. Mean (SD) PASI value decreased from 7.3 (4.8) to 2.1 (2.7) after 4 weeks. More than 90% of patients previously treated for psoriasis evaluated the Cal/BD foam more effective, easier to use and better tolerated compared to previous topical treatments at PPQ. This observational study provides real-life evidence of a high level of satisfaction with effectiveness and convenience of the Cal/BD foam in a cohort of plaque psoriasis patients, with an objective improvement in PASI.

Published
2021

12. The effect of COVID-19 emergency in the management of melanoma in Italy

Author

Anichini, A., Asero, S., Bersanelli, M., Caraco, C., De Giorgi, V., Di Giacomo, A. M., Feliciani, C., Ferraresi, V., Ghiorzo, P., Grimaldi, A. M., Guida, M., Mandala, M., Massi, D., Mocellin, S., Palmieri, G., Patuzzo, R., Pizzichetta, M. A., Ricci, R., Rossi, G., Quaglino, P., Queirolo, P., Senetta, R., Stanganelli, I., Tucci, M., Anichini, A., Asero, S., Bersanelli, M., Caraco, C., De Giorgi, V., Di Giacomo, A. M., Feliciani, C., Ferraresi, V., Ghiorzo, P., Grimaldi, A. M., Guida, M., Mandala, M., Massi, D., Mocellin, S., Palmieri, G., Patuzzo, R., Pizzichetta, M. A., Ricci, R., Rossi, G., Quaglino, P., Queirolo, P., Senetta, R., Stanganelli, I., and Tucci, M.

Subjects
medicine.medical_specialty, Telemedicine, Coronavirus disease 2019 (COVID-19), business.industry, Melanoma, Sentinel lymph node, COVID-19, Italy, management, Dermatology, lcsh:RL1-803, medicine.disease, Article, Management, Health services, Pandemic, medicine, lcsh:Dermatology, Skin melanoma, Intensive care medicine, business, Melanoma diagnosis
Abstract

The COVID-19 pandemic has severely hampered the functioning of any health system, absorbing a considerable amount of resources and with the threat of widespread infection in the health services. The present survey has been carried out in Italy to evaluate if and how COVID-19 also affected skin melanoma management. We enrolled 13 Italian centres highly qualified in the diagnosis and care of skin melanoma. We compared a set of information evaluating the amount of activity for melanoma performed during February-April 2020 with the same quarter in 2019. The number of new melanoma diagnosis, biopsies, wide local excisions, overall pathology reports decreased. However, the most severe cases seem promptly managed with sentinel lymph node biopsies, new systemic treatments (north) and the total number of (advanced) treated patients (centre-south). The COVID-19 experience has underlined the need to exploit the help which may come from telemedicine.

Published
2021

14. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I

Author

Rashid, H., primary, Lamberts, A., additional, Borradori, L., additional, Alberti‐Violetti, S., additional, Barry, R.J., additional, Caproni, M., additional, Carey, B., additional, Carrozzo, M., additional, Caux, F., additional, Cianchini, G., additional, Corrà, A., additional, Diercks, G.F.H., additional, Dikkers, F.G., additional, Di Zenzo, G., additional, Feliciani, C., additional, Geerling, G., additional, Genovese, G., additional, Hertl, M., additional, Joly, P., additional, Marzano, A.V., additional, Meijer, J.M., additional, Mercadante, V., additional, Murrell, D.F., additional, Ormond, M., additional, Pas, H.H., additional, Patsatsi, A., additional, Prost, C., additional, Rauz, S., additional, van Rhijn, B.D., additional, Roth, M., additional, Schmidt, E., additional, Setterfield, J., additional, Zambruno, G., additional, Zillikens, D., additional, and Horváth, B., additional

Published
2021
Full Text
View/download PDF

17. S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)

Author

Görög, A., primary, Antiga, E., additional, Caproni, M., additional, Cianchini, G., additional, De, D., additional, Dmochowski, M., additional, Dolinsek, J., additional, Drenovska, K., additional, Feliciani, C., additional, Hervonen, K., additional, Lakos Jukic, I., additional, Kinyó, Á., additional, Koltai, T., additional, Korponay‐Szabó, I., additional, Marzano, A.V., additional, Patsatsi, A., additional, Rose, C., additional, Salmi, T., additional, Schmidt, E., additional, Setterfield, J., additional, Shahid, M., additional, Sitaru, C., additional, Uzun, S., additional, Valitutti, F., additional, Vassileva, S., additional, Yayli, S., additional, and Sárdy, M., additional

Published
2021
Full Text
View/download PDF

18. Systematic experimental investigation of the obstacle effect during non-competitive and extremely competitive evacuations

Author

Feliciani, C. (Claudio), Zuriguel-Ballaz, I. (Iker), Montero, Á. (Ángel), Maza-Ozcoidi, D. (Diego), and Nishinari, K. (Katsuhiro)

Subjects
Física
Abstract

Although some experimental evidence showed that an obstacle placed in front of a door allows making people's evacuations faster, the efficacy of such a solution has been debated for over 15 years. Researchers are split between those who found the obstacle beneficial and those who could not find a significant difference without it. One of the reasons for the several conclusions lies in the variety of the experiments performed so far, both in terms of competitiveness among participants, geometrical configuration and number of participants. In this work, two unique datasets relative to evacuations with/without obstacle and comprising low and high competitiveness are analyzed using state-of-the-art definitions for crowd dynamics. In particular, the so-called congestion level is employed to measure the smoothness of collective motion. Results for extreme conditions show that, on the overall, the obstacle does not reduce density and congestion level and it could rather slightly increase it. From this perspective, the obstacle was found simply shifting the dangerous spots from the area in front of the exit to the regions between the obstacle and the wall. On the other side, it was however confirmed, that the obstacle can stabilize longitudinal crowd waves, thus reducing the risk of trampling, which could be as important (in terms of safety) as improving the evacuation time.

Published
2020

24. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

Author

Joly, P., primary, Horvath, B., additional, Patsatsi, Α, additional, Uzun, S., additional, Bech, R., additional, Beissert, S., additional, Bergman, R., additional, Bernard, P., additional, Borradori, L., additional, Caproni, M., additional, Caux, F., additional, Cianchini, G., additional, Daneshpazhooh, M., additional, De, D, additional, Dmochowski, M., additional, Drenovska, K., additional, Ehrchen, J., additional, Feliciani, C., additional, Goebeler, M., additional, Groves, R., additional, Guenther, C., additional, Hofmann, S., additional, Ioannides, D., additional, Kowalewski, C., additional, Ludwig, R., additional, Lim, Y.L., additional, Marinovic, B., additional, Marzano, A.V., additional, Mascaró, J.M., additional, Mimouni, D., additional, Murrell, D.F., additional, Pincelli, C., additional, Squarcioni, C.P., additional, Sárdy, M., additional, Setterfield, J., additional, Sprecher, E., additional, Vassileva, S., additional, Wozniak, K., additional, Yayli, S., additional, Zambruno, G., additional, Zillikens, D., additional, Hertl, M., additional, and Schmidt, E., additional

Published
2020
Full Text
View/download PDF

27. Efficacité et tolérance de la prednisone à 0,5 mg/kg/j en traitement initial de la pemphigoïde bulleuse

Author

Bastos, S., primary, Hebert, V., additional, Vassileva, S., additional, Patsatsi, A., additional, Meijer, J., additional, Quéreux, G., additional, Bedane, C., additional, Prost-Squarcioni, C., additional, Debardieux, S., additional, Oro, S., additional, Chaby, G., additional, D’Incan, M., additional, Litrowski, N., additional, Boulard, C., additional, Lunardon, L., additional, Kiritsi, D., additional, Jedlickova, H., additional, Feliciani, C., additional, Roussel, A., additional, Kottler, D., additional, Plantin, P., additional, Richard, M.-A., additional, Friedrichsen, L., additional, Abasq, C., additional, Duvert Lehembre, S., additional, Gottlieb, J., additional, Zebrowska, A., additional, Hofmann, S., additional, and Joly, P., additional

Published
2019
Full Text
View/download PDF

28. Italian guidelines in pemphigus - adapted from the European Dermatology Forum (EDF) and European Academy of Dermatology and Venerology (EADV)

Author

Feliciani C, Cozzani E, Marzano AV, Caproni M, Di Zenzo G, Calzavara-Pinton P, 'Cutaneous Immunology\\' group of SIDeMaST (Alaibac M, Antiga E, Arisi M, Assalve D, Atzori L, Babino G, Balato A, Balato N, Barbagallo T, Belloni Fortina A, Berardesca E, Berti E, Borghi A, Brazzelli V, Brumana MB, Brusati C, Caccavale S, Caldarola G, Campanati A, Caposiena Caro RD, Coati I, Conti A, Costanzo A, Dattola A, De Simone C, Di Cesare A, Di Lernia V, Di Zenzo GM, Fania L, Filosa G, Filotico R, Fusano M, Gerarda Galluccio A, Ganzetti G, Gisondi P, Guarneri F, Hansel K, Javor S, La Placa M, Liberati G, Lora V, Merlo G, Nasca MR, Nigro A, Noal C, Offidani A, Papini M, Parodi A, Patrizi A, Peserico A, Piaserico S, Prignano F, Quaglino P, Rossi M, Satta R, Schena D, Sena P, Simonetti O, Stan TR, Stingeni L, Talamonti M, Tavecchio S, Tognetti L, Vascellaro A, Vassallo C, Venturini M, Zampetti A, Zanca A)., Feliciani, Claudio, Cozzani, Emanuele, Marzano, Angelo V., Caproni, Marzia, Di Zenzo, Giovanni, Calzavara-Pinton, Piergiacomo, La placa M, Patrizi a, Feliciani, C, Cozzani, E, Marzano, Av, Caproni, M, Di Zenzo, G, Calzavara-Pinton, P, 'Cutaneous Immunology' group of SIDeMaST (Alaibac, M, Antiga, E, Arisi, M, Assalve, D, Atzori, L, Babino, G, Balato, A, Balato, N, Barbagallo, T, Belloni Fortina, A, Berardesca, E, Berti, E, Borghi, A, Brazzelli, V, Brumana, Mb, Brusati, C, Caccavale, S, Caldarola, G, Campanati, A, Caposiena Caro, Rd, Coati, I, Conti, A, Costanzo, A, Dattola, A, De Simone, C, Di Cesare, A, Di Lernia, V, Di Zenzo, Gm, Fania, L, Filosa, G, Filotico, R, Fusano, M, Gerarda Galluccio, A, Ganzetti, G, Gisondi, P, Guarneri, F, Hansel, K, Javor, S, La Placa, M, Liberati, G, Lora, V, Merlo, G, Nasca, Mr, Nigro, A, Noal, C, Offidani, A, Papini, M, Parodi, A, Patrizi, A, Peserico, A, Piaserico, S, Prignano, F, Quaglino, P, Rossi, M, Satta, R, Schena, D, Sena, P, Simonetti, O, Stan, Tr, Stingeni, L, Talamonti, M, Tavecchio, S, Tognetti, L, Vascellaro, A, Vassallo, C, Venturini, M, Zampetti, A, and Zanca, A).

Subjects
Male, medicine.medical_specialty, Venereology, Pemphigus - Guidelines - Skin diseases, Vesiculobullous, Autoantibodies, Evidence-Based Medicine, Female, Humans, Italy, Pemphigus, Skin, Socio-culturale, Dermatology, Desmoglein, Pemphigu, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Settore MED/35, Medicine, Skin pathology, skin and connective tissue diseases, Vesiculobullou, integumentary system, business.industry, Guideline, Evidence-based medicine, medicine.disease, Autoantibodie, 2708, 030220 oncology & carcinogenesis, Pemphigus - Guidelines - Skin disease, business, Blistering disease, Human
Abstract

Pemphigus is a life threatening autoimmune epidermal blistering disease involving skin and mucous membranes. Pemphigus usually affects middle age men and women involving oral mucosa first and then spreading on the skin. It is caused by the presence of autoantibodies (IgG and less frequently by IgA) directed against desmogleins, and/or other glycoproteins that plays a critical role in cell-cell attachment. Upon a predisposing genetic background, different agents have been shown to act as triggers for the pathogenesis of pemphigus. This guideline for the diagnosis and treatment of pemphigus has been developed by an Italian group of experts taking in account the Italian legislation and local pharmacological governance. Guidelines are adapted from the original article under the guidance of the European Dermatology Forum in collaboration with the European Academy of Dermatology and Venereology. It summarizes evidence-based and expert-based recommendations (S2 level).

Published
2018

31. International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg−1 per day starting dose of oral corticosteroids to treat bullous pemphigoid.

Author

Hébert, V., Bastos, S., Drenovska, K., Meijer, J., Ingen‐Housz‐Oro, S., Bedane, C., Lunardon, L., Debarbieux, S., Jedlickova, H., Caux, F., Chaby, G., D'Incan, M., Feliciani, C., Boulard, C., Schumacher, N., Schmidt, E., Roussel, A., Richard, M.A., Gottlieb, J., and Ferranti, V.

Subjects
BULLOUS pemphigoid, KARNOFSKY Performance Status, CORTICOSTEROIDS, SCIENTIFIC observation, OVERALL survival
Abstract

Summary: Background: European guidelines propose a 0·5 mg kg−1 per day dose of oral prednisone as initial treatment for bullous pemphigoid (BP). We assessed the safety and efficacy of this regimen depending on BP extent and general condition of the patients. Methods: In a prospective international study, we consecutively included all patients diagnosed with BP. Patients received a 0·5 mg kg−1 per day dose of prednisone, which was then gradually tapered 15 days after disease control, with the aim of stopping prednisone or maintaining minimal treatment (0·1 mg kg−1 per day) within 6 months after the start of treatment. The two coprimary endpoints were control of disease activity at day 21 and 1‐year overall survival. Disease severity was assessed according to the Bullous Pemphigoid Disease Area Index (BPDAI) score. Results: In total, 198 patients were included between 2015 and 2017. The final analysis comprised 190 patients with a mean age of 80·9 (SD 9·1) years. Control of disease activity was achieved at day 21 in 119 patients [62·6%, 95% confidence interval (CI) 55·3–69.5]; 18 of 24 patients (75%, 95% CI 53·3–90·2), 75 of 110 patients (68·8%, 95% CI 59·2–77·3) and 26 of 56 patients (46.4%, 95% CI 33·0–60·3) had mild, moderate and severe BP, respectively (P = 0·0218). A total of 30 patients died during the study. The overall Kaplan–Meier 1‐year survival was 82·6% (95% CI 76·3–87·4) corresponding to 90·9%, 83·0% and 80·0% rates in patients with mild, moderate and severe BP, respectively (P = 0·5). Thresholds of 49 points for BPDAI score and 70 points for Karnofsky score yielded maximal Youden index values with respect to disease control at day 21 and 1‐year survival, respectively. Conclusions: A 0·5 mg kg−1 per day dose of prednisone is a valuable therapeutic option in patients with mild or moderate BP whose general condition allows them to be autonomous. What is already known about this topic? Superpotent topical corticosteroids are the gold standard treatment for bullous pemphigoid (BP), whatever the severity.High doses of oral corticosteroids are effective but poorly tolerated in patients with BP.Medium doses of oral corticosteroids are effective in paucibullous BP, but their efficacy in severe forms has not yet been assessed. What does this study add? Medium doses of oral corticosteroids have poor efficacy in severe BP.A baseline Bullous Pemphigoid Disease Area Index score < 50 and a Karnofsky score ≥ 70 are predictors of treatment efficacy and low mortality, respectively. Linked Comment: H.Y. Lee. Br J Dermatol 2021; 185:1093–1094. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

32. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II.

Author

Schmidt, E., Rashid, H., Marzano, A.V., Lamberts, A., Di Zenzo, G., Diercks, G.F.H., Alberti‐Violetti, S., Barry, R.J., Borradori, L., Caproni, M., Carey, B., Carrozzo, M., Cianchini, G., Corrà, A., Dikkers, F.G., Feliciani, C., Geerling, G., Genovese, G., Hertl, M., and Joly, P.

Subjects
DIAGNOSIS, MUCOUS membranes, COMPLEMENT (Immunology), PHYSICIANS, DERMATOLOGY, BEHCET'S disease
Abstract

This guideline has been initiated by the task force Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology, including physicians from all relevant disciplines and patient organizations. It is a S3 consensus‐based guideline that systematically reviewed the literature on mucous membrane pemphigoid (MMP) in the MEDLINE and EMBASE databases until June 2019, with no limitations on language. While the first part of this guideline addressed methodology, as well as epidemiology, terminology, aetiology, clinical presentation and outcome measures in MMP, the second part presents the diagnostics and management of MMP. MMP should be suspected in cases with predominant mucosal lesions. Direct immunofluorescence microscopy to detect tissue‐bound IgG, IgA and/or complement C3, combined with serological testing for circulating autoantibodies are recommended. In most patients, serum autoantibodies are present only in low levels and in variable proportions, depending on the clinical sites involved. Circulating autoantibodies are determined by indirect IF assays using tissue substrates, or ELISA using different recombinant forms of the target antigens or immunoblotting using different substrates. The major target antigen in MMP is type XVII collagen (BP180), although in 10–25% of patients laminin 332 is recognized. In 25–30% of MMP patients with anti‐laminin 332 reactivity, malignancies have been associated. As first‐line treatment of mild/moderate MMP, dapsone, methotrexate or tetracyclines and/or topical corticosteroids are recommended. For severe MMP, dapsone and oral or intravenous cyclophosphamide and/or oral corticosteroids are recommended as first‐line regimens. Additional recommendations are given, tailored to treatment of single‐site MMP such as oral, ocular, laryngeal, oesophageal and genital MMP, as well as the diagnosis of ocular MMP. Treatment recommendations are limited by the complete lack of high‐quality randomized controlled trials. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

35. Bullous Wells syndrome

Author

Feliciani, C, Motta, A, Tortorella, R, De Benedetto, A, Amerio, P, and Tulli, A

Published
2006

38. Healthcare and safety of patients with melanoma during the COVID‐19 Pandemic in Italy.

Author

Caini, S., Brusasco, M., Niero, G., De Giorgi, V., Lombardo, M., Massone, C., Medri, M., Palmieri, G., Pizzichetta, M.A., Quaglino, P., Satta, R., Feliciani, C., Gandini, S., and Stanganelli, I.

Subjects
COVID-19 pandemic, PATIENT safety, MELANOMA, MEDICAL care, HEALTH facilities, DERMATOLOGISTS, PATIENT surveys
Abstract

Finally, teledermatology was not investigated in our survey due to ongoing clinical validation and medico-legal restrictions..9,10 In conclusion, healthcare quality and patient safety appear to have been generally guaranteed in melanoma management during the COVID-19 pandemic in Italy. Healthcare and safety of patients with melanoma during the COVID-19 Pandemic in Italy Effects of the COVID-19 pandemic on care of melanoma patients in Berlin, Germany: the Mela-COVID survey. [Extracted from the article]

Published
2022
Full Text
View/download PDF

49. A case of acquired disseminated elastosis perforans serpiginosa in a patient with HIV, hepatitis B and hepatitis C successfully treated with narrowband ultraviolet B therapy.

Author

Di Nuzzo, S., Bertolani, M., Casanova, D., Manuguerra, R, Felici del Giudice, M. B., and Feliciani, C.

Subjects
HEPATITIS B, HIV-positive persons, HEPATITIS C, BLOODBORNE infections
Abstract

Click here for the corresponding questions to this CME article. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results